Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
May 2, 2023 09:58 AM EDTUpdated 01:24 PM
R&D
Pharma

Pfiz­er culls some Are­na-ac­quired pro­grams as it looks to­ward new launch­es

Kyle LaHucik

Senior Reporter

As Pfiz­er works to con­sum­mate a mega-merg­er with Seagen to prop up its on­col­o­gy pipeline and prod­uct port­fo­lio, the Big Phar­ma dis­closed some pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times